Giovanni Cecere - 18 Feb 2026 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Reporting relationship: Chief Commercial Officer
Issuer ticker: TMDX
Reported as of: 18 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Feb 2026, 16:07:02 UTC
Prior SEC filing: 12 Feb 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Gerardo Hernandez, Attorney-in-Fact

Key filing fact

Giovanni Cecere filed Form 4 for TransMedics Group, Inc. (TMDX) on 20 Feb 2026.

Key facts

This page summarizes Giovanni Cecere's Form 4 filing for TransMedics Group, Inc. (TMDX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 Feb 2026, 16:07.

Change

Previous filing in this sequence was filed on 12 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002110539 Primary reporting owner

Cecere Giovanni

Relationship: Chief Commercial Officer
Address: C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER
Signature: By: /s/ Gerardo Hernandez, Attorney-in-Fact
Signature date: 20 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TMDX transaction

Common Stock

Award

Transaction value: $0
Shares: +11,082
Change %: +139%
Price: $0.000000
Shares after: 19,057
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TMDX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +16,734
Change %
Price: $0.000000
Shares after: 16,734
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,734
Exercise price: $135.50
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Consists of 11,082 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

The option vests as to 25% of the shares underlying the option on February 18, 2027 and as to the remaining shares in equal monthly installments over three years thereafter, subject to continued service.